True to the origin of our name, Metamorphosis, MorphoSys has transformed from an R&D technology provider into a global commercial-stage biopharmaceutical company.
Our History
Our Successful Journey
1992
MorphoSys founded in Martinsried, Germany by Dr. Simon Moroney and Prof. Dr. Andreas Plückthun
1994
Invention of the HuCAL Concept, synthetic library consisting of human antibody sequences for the generation of highly specific, fully human antibodies. Inventor: Achim Knappik, Dr. Simon Moroney, Prof. Dr. Andreas Plückthun (and others)
1997
Move to IZB Gründerzentrum with ~30 employees; first partnership with Pharmacia & Upjohn
1999
MorphoSys is listed on the Frankfurt stock exchange; partnership with Bayer
2000
Move to our own building in Martinsried, ~100 employees
2000-2007
Growth through partnerships: Novartis, Janssen, Schering-Plough, Pfizer, Merck
Since 2007
Own drug development, e.g. with Xencor, GSK and others
2016
Move to new building in Planegg: state-of-the-art office and lab, unifying all teams under one roof
2017
Tremfya® is the first drug based on MorphoSys’ antibody technology to receive regulatory approval. Developed and marketed by Janssen for the treatment of plaque psoriasis
2018
MorphoSys is listed on NASDAQ; MorphoSys US Inc. is established; MorphoSys and I-Mab enter strategic development and commercialization agreement for MOR210/TJ210
2019
Jean-Paul Kress appointed as MorphoSys CEO in September
January 2020
MorphoSys and Incyte enter into collaboration and licensing agreement to further develop and commercialize tafasitamab globally
July 2020
The U.S. Food and Drug Administration (FDA) grants accelerated approval for Monjuvi® (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma
November 2020
MorphoSys and Cherry Biolabs entered into a licensing agreement for innovative, multispecific Hemibody technology; MorphoSys and Xencor enter into collaboration exploring further combinations with tafasitamab and Xencor’s CD20xCD3 bispecific plamotamab
July 2021
Acquisition of Constellation Pharmaceuticals, a U.S. biotech company that adds exciting, pioneering science and two new product candidates to our pipeline
August 2021
Conditional approvals for Minjuvi® (tafasitamab) in the European Union and Canada in combination with lenalidomide in patients with a certain type of lymphoma